Clinical Trials Logo
  1. Home
  2. Frontal Fibrosing Alopecia
  3. NCT04409041

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia Clinical Trial

Official title:
Oral Low-Dose Naltrexone in the Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia; an Uncontrolled Open-label Prospective Study

Clinical Trial Summary

Oral naltrexone was initially FDA approved to treat opioid use disorder and alcohol dependence at doses from 50-100mg/day. At lower doses of 1-5mg/day, naltrexone has been used off-label with success in treatment of several dermatologic conditions including the scarring hair loss disease lichen planopilaris. A recent case series of four patients with lichen planopilaris and a subtype, frontal fibrosing alopecia, treated with oral low-dose naltrexone at 3mg daily showed reduction of itch, clinical evidence of inflammation of the scalp, and of disease progression. There were no reported adverse events. Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04409041
Study type Interventional
Source Washington University School of Medicine
Contact
Status Completed
Phase Phase 2
Start date September 1, 2019
Completion date December 31, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Enrolling by invitation NCT06202560 - Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study N/A
Not yet recruiting NCT03335228 - Platelet Rich Plasma for Frontal Fibrosing Alopecia N/A
Not yet recruiting NCT02467101 - Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia N/A
Recruiting NCT03422640 - Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Phase 4
Completed NCT03346668 - Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia Early Phase 1
Active, not recruiting NCT03082560 - Design and Validation of a New Assessment Tool for Lichen Planopilaris
Completed NCT04342091 - Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling N/A
Recruiting NCT06240351 - A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) Phase 4
Completed NCT05332366 - A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia Phase 2